Actively Recruiting
Research on Early Markers of Diabetic Nephropathy Using Lipid Analysis in Adults with Type 2 Diabetes
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2021-07-20
1000
Participants Needed
1
Research Sites
261 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating diabetic nephropathy DN, a serious kidney complication in people with diabetes that can lead to chronic kidney disease and end-stage renal disease. Current early diagnostic tools like albuminuria and estimated glomerular filtration rate eGFR lack sensitivity and specificity. This study aims to identify new lipid biomarkers using mass spectrometry to detect early diabetic kidney damage more accurately and ultimately apply these findings in clinical practice. The study combines clinical and laboratory research by collecting serum, plasma, and urine samples from participants, including people with early diabetic kidney disease, type 2 diabetes, and healthy adults. Researchers record personal data, medical history, physical exams, and laboratory results. Participants are enrolled after meeting criteria and providing consent, with samples and data collected at baseline and annually for at least five years. Participants undergo yearly follow-ups involving clinical evaluations, laboratory tests, and collection of biological samples for metabolomics research. Researchers track urinary albumin creatinine ratio UACR over five years as the primary outcome. The study aims to explore mechanisms of diabetic nephropathy and discover new biomarkers and treatments through long-term, multi-center observation and analysis.
CONDITIONS
Brief Title
Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics.
Research Team
Z
Zheng Chao, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here